Quanterix (QTRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Puneet Souda from Leerink Partners downgraded the rating on the stock to a Hold and gave it a $8.00 price target.
Puneet Souda has given his Hold rating due to a combination of factors impacting Quanterix’s strategic and financial outlook. The company is in the process of acquiring Akoya Biosciences, but the amended terms of the deal, which significantly reduce its value, still pose challenges. Quanterix is facing difficulties in integrating Akoya while simultaneously managing its own supply-chain issues and addressing market pressures in its core academic and pharmaceutical sectors. These challenges are compounded by the competitive landscape in the Alzheimer’s diagnostics market, where Quanterix is trying to establish a foothold.
Additionally, the financial projections for Quanterix and Akoya suggest a need to revise growth estimates downward due to market headwinds, which could strain the company’s cash resources. The combined entity’s cash runway is expected to extend only into the second half of 2026, creating an overhang. As a result, Souda has adjusted the price target for Quanterix to $8, reflecting these concerns about execution risks and financial sustainability.